Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes
The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective negative genes.
Liver Metastases of Colorectal Cancer
DRUG: Capecitabine|DRUG: oxaliplatin|DRUG: Cetuximab|DRUG: Oxaliplatin|DRUG: Leucovorin|DRUG: 5-FU
Objective Response Rate, every 2 weeks
overall survival, Around 2 years
The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective negative genes.